National Cancer Institute; Notice of Meeting, 22753 [E9-11236]

Download as PDF Federal Register / Vol. 74, No. 92 / Thursday, May 14, 2009 / Notices available, what information FDA recommends you submit in support of a request for a fee waiver or reduction, how to submit such a request, and FDA’s process for reviewing requests. FDA is issuing this level 1 final guidance document for immediate implementation consistent with FDA’s GGPs regulation (21 CFR 10.115). Prior public participation is not feasible because the guidance concerns statutory requirements that FDA must implement immediately. AGDUFA’s user fee provisions are already in effect, and it is essential for the agency to provide guidance on how to request fee waivers and reductions as quickly as possible. If FDA receives comments on this final guidance, it will review the comments and revise the guidance if appropriate. II. Significance of Guidance This level 1 guidance is being issued consistent with FDA’s GGPs regulation (21 CFR 10.115). The guidance represents the agency’s current thinking on the fee waiver provisions of AGDUFA. It does not create or confer any rights for or on any person and will not operate to bind FDA or the public. Alternative methods may be used as long as they satisfy the requirements of the applicable statutes and regulations. III. Paperwork Reduction Act of 1995 FDA concludes that there are no collections of information under the Paperwork Reduction Act of 1995. IV. Comments Interested persons may submit to the Division of Dockets Management (see ADDRESSES) written or electronic comments regarding this guidance. Submit a single copy of electronic comments or two paper copies of any mailed comments, except that individuals may submit one paper copy. Comments are to be identified with the docket number found in brackets in the heading of this document. A copy of the guidance and received comments are available for public examination in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday. V. Electronic Access pwalker on PROD1PC71 with NOTICES Persons with access to the internet may obtain the guidance at either https:// www.fda.gov/cvm or https:// www.regulations.gov. Dated: May 7, 2009. Jeffrey Shuren, Associate Commissioner for Policy and Planning. [FR Doc. E9–11218 Filed 5–13–09; 8:45 am] BILLING CODE 4160–01–S VerDate Nov<24>2008 17:37 May 13, 2009 Jkt 217001 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Cancer Institute; Notice of Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the meeting of the National Cancer Advisory Board. The meeting will be open to the public as indicated below, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. A portion of the meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4), and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Cancer Advisory Board Subcommittee on Cancer Centers. Open: June 10, 2009, 6 p.m. to 7:30 p.m. Agenda: Discussion on Cancer Centers. Place: Bethesda Hyatt Regency Hotel, One Metro Center, Bethesda, MD 20814. Contact Person: Dr. Linda K. Weiss, Executive Secretary, NCAB Subcommittee on Cancer Centers, National Cancer Institute, National Institutes of Health, 6116 Executive Boulevard, Suite 700, Bethesda, MD 20892– 8345, (301) 496–8531. Name of Committee: National Cancer Advisory Board. Open: June 11, 2009, 8 a.m. to 4 p.m. Agenda: Program reports and presentations; business of the Board. Place: National Institutes of Health, 9000 Rockville Pike, Building 31, C Wing, 6th Floor, Conference Room 10, Bethesda, MD 20892. Contact Person: Dr. Paulette S. Gray, Executive Secretary, National Cancer Institute, National Institutes of Health, 6116 Executive Boulevard, 8th Floor, Room 8001, Bethesda, MD 20892–8327. (301) 496–5147. Name of Committee: National Cancer Advisory Board. Closed: June 11, 2009, 4 p.m. to adjournment. Agenda: Review of grant applications. Place: National Institutes of Health, 9000 Rockville Pike, Building 31, C Wing, 6th Floor, Conference Room 10, Bethesda, MD 20892. PO 00000 Frm 00028 Fmt 4703 Sfmt 4703 22753 Contact Person: Dr. Paulette S. Gray, Executive Secretary, National Cancer Institute, National Institutes of Health, 6116 Executive Boulevard, 8th Floor, Room 8001, Bethesda, MD 20892–8327, (301) 496–5147. Name of Committee: National Cancer Advisory Board. Open: June 12, 2009, 8:30 a.m. to 12 p.m. Agenda: Program reports and presentations; business of the Board. Place: National Institutes of Health, 9000 Rockville Pike, Building 31, C Wing, 6th Floor, Conference Room 10, Bethesda, MD 20892. Contact Person: Dr. Paulette S. Gray, Executive Secretary, National Cancer Institute, National Institutes of Health, 6116 Executive Boulevard, 8th Floor, Room 8001, Bethesda, MD 20892–8327, (301) 496–5147. Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver’s license, or passport) and to state the purpose of their visit. Information is also available on the Institute’s/Center’s home page: deainfo.nci.nih.gov/advisory/ncab.htm, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Dated: May 5, 2009. Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy. [FR Doc. E9–11236 Filed 5–13–09; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings. E:\FR\FM\14MYN1.SGM 14MYN1

Agencies

[Federal Register Volume 74, Number 92 (Thursday, May 14, 2009)]
[Notices]
[Page 22753]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-11236]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Cancer Institute; Notice of Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of the meeting of 
the National Cancer Advisory Board.
    The meeting will be open to the public as indicated below, with 
attendance limited to space available. Individuals who plan to attend 
and need special assistance, such as sign language interpretation or 
other reasonable accommodations, should notify the Contact Person 
listed below in advance of the meeting.
    A portion of the meeting will be closed to the public in accordance 
with the provisions set forth in sections 552b(c)(4), and 552b(c)(6), 
Title 5 U.S.C., as amended. The grant applications and the discussions 
could disclose confidential trade secrets or commercial property such 
as patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Cancer Advisory Board Subcommittee 
on Cancer Centers.
    Open: June 10, 2009, 6 p.m. to 7:30 p.m.
    Agenda: Discussion on Cancer Centers.
    Place: Bethesda Hyatt Regency Hotel, One Metro Center, Bethesda, 
MD 20814.
    Contact Person: Dr. Linda K. Weiss, Executive Secretary, NCAB 
Subcommittee on Cancer Centers, National Cancer Institute, National 
Institutes of Health, 6116 Executive Boulevard, Suite 700, Bethesda, 
MD 20892-8345, (301) 496-8531.

    Name of Committee: National Cancer Advisory Board.
    Open: June 11, 2009, 8 a.m. to 4 p.m.
    Agenda: Program reports and presentations; business of the 
Board.
    Place: National Institutes of Health, 9000 Rockville Pike, 
Building 31, C Wing, 6th Floor, Conference Room 10, Bethesda, MD 
20892.
    Contact Person: Dr. Paulette S. Gray, Executive Secretary, 
National Cancer Institute, National Institutes of Health, 6116 
Executive Boulevard, 8th Floor, Room 8001, Bethesda, MD 20892-8327. 
(301) 496-5147.
    Name of Committee: National Cancer Advisory Board.
    Closed: June 11, 2009, 4 p.m. to adjournment.
    Agenda: Review of grant applications.
    Place: National Institutes of Health, 9000 Rockville Pike, 
Building 31, C Wing, 6th Floor, Conference Room 10, Bethesda, MD 
20892.
    Contact Person: Dr. Paulette S. Gray, Executive Secretary, 
National Cancer Institute, National Institutes of Health, 6116 
Executive Boulevard, 8th Floor, Room 8001, Bethesda, MD 20892-8327, 
(301) 496-5147.

    Name of Committee: National Cancer Advisory Board.
    Open: June 12, 2009, 8:30 a.m. to 12 p.m.
    Agenda: Program reports and presentations; business of the 
Board.
    Place: National Institutes of Health, 9000 Rockville Pike, 
Building 31, C Wing, 6th Floor, Conference Room 10, Bethesda, MD 
20892.
    Contact Person: Dr. Paulette S. Gray, Executive Secretary, 
National Cancer Institute, National Institutes of Health, 6116 
Executive Boulevard, 8th Floor, Room 8001, Bethesda, MD 20892-8327, 
(301) 496-5147.

    Any interested person may file written comments with the 
committee by forwarding the statement to the Contact Person listed 
on this notice. The statement should include the name, address, 
telephone number and when applicable, the business or professional 
affiliation of the interested person.
    In the interest of security, NIH has instituted stringent 
procedures for entrance onto the NIH campus. All visitor vehicles, 
including taxicabs, hotel, and airport shuttles will be inspected 
before being allowed on campus. Visitors will be asked to show one 
form of identification (for example, a government-issued photo ID, 
driver's license, or passport) and to state the purpose of their 
visit.
    Information is also available on the Institute's/Center's home 
page: deainfo.nci.nih.gov/advisory/ncab.htm, where an agenda and any 
additional information for the meeting will be posted when 
available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, 
Cancer Construction; 93.393, Cancer Cause and Prevention Research; 
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer 
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer 
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer 
Control, National Institutes of Health, HHS)

    Dated: May 5, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. E9-11236 Filed 5-13-09; 8:45 am]
BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.